Stockholm, May 19, 2022 - Intervacc AB (publ) announces the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by Staphylococcus ... Read more
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Tuesday 14 June 2022 at 5.00 p.m. at Good Morning Hotel, ... Read more
Stockholm, April 25, 2022 - Intervacc AB (publ) announces positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus ... Read more
Stockholm, April 6, 2022 - Intervacc AB (publ) announces that the company's 2021 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is ... Read more
Stockholm, March 23, 2022 - Intervacc announces today that the first batch of Strangvac®, a vaccine against equine Strangles, has been released for sale in Sweden.
“Strangvac® has now ... Read more
